TrialSignal
Clinical trial intelligence report
A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00954915
Status
TERMINATED
Phase
Phase 2a
Sponsor
MacroGenics
Executive brief
Investment-Ready Snapshot
The study aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab, a monoclonal antibody, in adults with moderate to severe psoriasis. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00954915
Indication
Psoriasis
Modality
monoclonal antibody
Target
Psoriasis
Intervention
teplizumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.